Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Pharmaceutical preparations company · NV · FY ends Apr
$0.07
+$0.00 (+0.00%)
Price from 2 days ago
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$507K
▲ +64.7% YoY
Op. Margin
—
ROIC
-1096.20%
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$73K
▲ +39.6% YoY
Net Debt
-$15K
Net Cash Position
Cash & Equiv.
$15K
Continue Research
SourceComputed from the 10-Q filed 12 Sept 2022, covering the period ending 31 Jul 2022, as reported to the SEC. Data last refreshed 2 Apr 2026. How this is calculated.
Price from market data, last close as of 14 Sept 2026. Fiscal year ends Apr. Sector medians are approximate S&P 500 benchmarks and update periodically.
Bioquest (BQST)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bioquest scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Bioquest scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,096.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BQST's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.